Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12617001199303
Ethics application status
Approved
Date submitted
10/08/2017
Date registered
16/08/2017
Date last updated
29/09/2024
Date data sharing statement initially provided
17/12/2018
Date results provided
29/09/2024
Type of registration
Prospectively registered

Titles & IDs
Public title
Medical Therapy versus Prostate Artery Embolisation in treatment naïve men with symptomatic benign prostate hyperplasia (MEDS vs PAE)
Scientific title
Medical Therapy versus Prostate Artery Embolisation in treatment naïve men with symptomatic benign prostate hyperplasia (MEDS vs PAE)
Secondary ID [1] 292629 0
None
Universal Trial Number (UTN)
U1111-1200-5385
Trial acronym
MEDS vs PAE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Benign prostate hyperplasia 304349 0
Condition category
Condition code
Renal and Urogenital 303683 303683 0 0
Other renal and urogenital disorders
Surgery 303684 303684 0 0
Surgical techniques

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
There are two treatment groups in this trial; prostate artery embolization (new intervention) and medical therapy (Duodart, current standard treatment).

Prostate artery embolisation procedures are performed by interventional radiologists experienced in prostate artery embolisation. The procedure takes approximately 120 minutes. Procedures will be performed with a right femoral or left brachial artery approach, using 4- or 5- French sheaths. 5-Fr 125 cm Impulse (Merit Medical, Utah, USA) and 4-Fr 120 cm Cobra Glidecath (Terumo, New Jersey, USA) catheters are combined with 150 cm standard Glidewires (Terumo, New Jersey, USA) to access the internal iliac arteries. Microcatheters 2.0Fr Progreat (Terumo, New Jersey, USA) or 1.7Fr SL-10 (Stryker, Michigan, USA) are used to selectively catheterise the prostate arteries over microwires, either 0.016” Radifocus Guidewire GT (Terumo, New Jersey, USA) or 0.014” Synchro Standard (Stryker, Michigan, USA). Following selective catheterisation of the prostate arteries and positioning of the microcatheter tip within the distal prostate artery, an on-table Dyna CT scan using hand-injected 1-2 ml contrast (Ultravist 300, Bayer, Leverkusen, Germany) in a 3 ml Medallion syringe (Merit Medical, Utah, USA) is performed and reviewed in three planes to assess for non-prostatic enhancement. Once the operators are confident that no off-target enhancement is evident, a single unit syringe of 250 micron Embozene (Celenova Biosciences, Texas, USA) is prepared by diluting the Embozene particles with full contrast to 1/16 (6.25%) of the original concentration. Embolisation is then performed by slowly injecting the diluted particles until complete stasis of the prostate artery has been achieved.

Medical therapy with Duodart, a fixed-dose combination of 0.5 mg Dutasteride (a 5-alpha reductase inhibitor) and 0.4 mg Tamsulosin (a-blocker) will be taken as a once daily oral tablet.

Patients in each group will be followed-up at six months post-treatment commencement and any patient who has not satisfactorily responsed to their treatment will be offered the other treatment option. Response to treatment will be assessed based on a range of parameters, these include; severity of symptoms (IPSS questionnaire with quality of life question); change in prostate volume (measured by ultrasound); change in bladder function (ultrasound and urodynamic testing); treatment side effects (questionnaire designed specifically for this study); and the patient's satisfaction with their response to treatment (questionnaire designed specifically for this study). Patient eligibility for cross over will be assessed on a case-by-case basis and permitted if; a) the patient is unsatisfied with their response to treatment and b) if the treating specialists (urologist and interventional radiologist) agree an improved response is likely with treatment crossover.
Intervention code [1] 298857 0
Treatment: Other
Intervention code [2] 298858 0
Treatment: Surgery
Comparator / control treatment
Medical therapy with Duodart, a fixed-dose combination of 0.5 mg Dutasteride (a 5-alpha reductase inhibitor) and 0.4 mg Tamsulosin (a-blocker). Duodart will be taken as one oral tablet once daily for the duration of this project (24 months, unless crossed over at 6 months). Adherence will be monitored during follow-up appointments and reasons for non-compliance, for example negative side effects, recorded.
Control group
Active

Outcomes
Primary outcome [1] 303050 0
To assess the efficacy of combined medical therapy (Duodart) versus PAE as frontline treatment for BPH in treatment-naïve patients, as assessed by: Absolute and % change in IPSS.
Timepoint [1] 303050 0
6-months (primary timepoint) and 24-months post-treatment initiation
Primary outcome [2] 303052 0
To assess the efficacy of combined medical therapy (Duodart) versus PAE as frontline treatment for BPH in treatment-naïve patients, as assessed by: Absolute and % change in QoL scores as assessed within the IPSS questionnaire.
Timepoint [2] 303052 0
6-months (primary timepoint) and 24-months post-treatment initiation
Secondary outcome [1] 337777 0
To further evaluate and compare medication and PAE treatment options by assessing: Change in urinary Qmax (peak flow rate, measured on ultrasound)
Timepoint [1] 337777 0
6-months and 24-months post-treatment initiation
Secondary outcome [2] 337778 0
To further evaluate and compare medication and PAE treatment options by assessing: Change in post-void residual volume (PVR, measured on ultrasound)
Timepoint [2] 337778 0
6-months and 24-months post-treatment initiation
Secondary outcome [3] 337779 0
To further evaluate and compare medication and PAE treatment options by assessing: Change in prostate volume (absolute and % reduction). Prostate volumes will be calculated from CT, MRI and ultrasound scan measurements
Timepoint [3] 337779 0
6-months and 24-months post-treatment initiation
Secondary outcome [4] 337780 0
To further evaluate and compare medication and PAE treatment options by assessing: Side effect/adverse outcome profile of medication v PAE (type of side-effects, severity and duration) . Side effect profiles will be assessed via a questionnaire designed for this study
Timepoint [4] 337780 0
6-months and 24-months post-treatment initiation
Secondary outcome [5] 337781 0
To further evaluate and compare medication and PAE treatment options by assessing: PSA levels via serum blood tests
Timepoint [5] 337781 0
6-months and 24-months post-treatment initiation
Secondary outcome [6] 337782 0
To further evaluate and compare medication and PAE treatment options by assessing: Changes in urodynamic study results pre and post treatment. The key urodynamic study test will be uroflowmetry (flow rate of urine) performed by a urologist.
Timepoint [6] 337782 0
6-months and 24-months post-treatment initiation
Secondary outcome [7] 337784 0
To further evaluate and compare medication and PAE treatment options by assessing: Overall satisfaction with treatment as assessed via a questionnaire specifically designed for use in this study
Timepoint [7] 337784 0
6-months and 24-months post-treatment initiation

Eligibility
Key inclusion criteria
BPH with prostate volume > 50cc
Moderate-severe lower urinary tract symptoms (IPSS >8)
Peak urinary flow <12ml/sec
Obstructive urodynamics
Treatment-naive, i.e. no previous medical therapy for BPH.
Minimum age
50 Years
Maximum age
80 Years
Sex
Males
Can healthy volunteers participate?
No
Key exclusion criteria
Prostate malignancy
Neurogenic bladder
Renal failure eGFR <35ml/min
Severe peripheral vascular disease
Urethral or bladder pathology
History of medical therapy for BPH.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Patients will be randomised to receive either combination medical therapy (Duodart) or to undergo a PAE procedure. Any patient who is not satisfied with their response to treatment by 6 months will be assessed and offered the alternative treatment option if the treating specialists (urologist and interventional radiologist) are in agreement that crossover has the potential to improve patient response.
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/09/2017
Actual
12/11/2018
Date of last participant enrolment
Anticipated
30/04/2022
Actual
13/07/2022
Date of last data collection
Anticipated
16/12/2022
Actual
31/10/2022
Sample size
Target
40
Accrual to date
Final
54
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 8757 0
The Wesley Hospital - Auchenflower
Recruitment postcode(s) [1] 16877 0
4066 - Auchenflower

Funding & Sponsors
Funding source category [1] 297260 0
Commercial sector/Industry
Name [1] 297260 0
Wesley Medical Imaging
Country [1] 297260 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Wesley Medical Imaging
Address
The Wesley Hospital
30 Chasely Street
Auchenflower, QLD, 4066
Country
Australia
Secondary sponsor category [1] 296233 0
None
Name [1] 296233 0
Address [1] 296233 0
Country [1] 296233 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 298377 0
UnitingCare Health Human Research Ethics Committee
Ethics committee address [1] 298377 0
Ethics committee country [1] 298377 0
Australia
Date submitted for ethics approval [1] 298377 0
20/06/2017
Approval date [1] 298377 0
19/09/2017
Ethics approval number [1] 298377 0
1735

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 76882 0
Dr Nicholas Brown
Address 76882 0
Wesley Medical Imaging
30 Chasely Street
Auchenflower, QLD, 4066
Country 76882 0
Australia
Phone 76882 0
+61 7 3371 9588
Fax 76882 0
Email 76882 0
[email protected]
Contact person for public queries
Name 76883 0
Sepinoud Firouzmand
Address 76883 0
Wesley Medical Imaging 30 Chasely Street Auchenflower, QLD, 4066
Country 76883 0
Australia
Phone 76883 0
+61 7 3371 9588
Fax 76883 0
Email 76883 0
[email protected]
Contact person for scientific queries
Name 76884 0
Sepinoud Firouzmand
Address 76884 0
Wesley Medical Imaging 30 Chasely Street Auchenflower, QLD, 4066
Country 76884 0
Australia
Phone 76884 0
+61 7 3371 9588
Fax 76884 0
Email 76884 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
Given the small number of participants (40 maximum in two treatment groups), data collected in this study is unlikely to be of value to meta-analysis by external investigators. However, the Principal Investigator would be happy to consider requests for IPD at a later date.


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.